Investors Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading on Tuesday. Stock traders acquired 20,530 put options on the company. This represents an increase of 32% compared to the typical volume of 15,579 put options.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Morgan Stanley lifted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded up $0.03 during trading hours on Tuesday, hitting $3.31. 7,962,734 shares of the company were exchanged, compared to its average volume of 18,321,672. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The company has a market capitalization of $1.76 billion, a PE ratio of -3.19 and a beta of 1.03. The firm has a fifty day simple moving average of $3.31 and a 200-day simple moving average of $3.44. Recursion Pharmaceuticals has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same period last year, the firm earned ($0.41) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals will post -0.9 earnings per share for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total value of $97,500.00. Following the transaction, the director owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This trade represents a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock valued at $478,874 over the last 90 days. 6.65% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at about $31,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth about $41,000. NewEdge Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock worth $56,000 after acquiring an additional 2,428 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Recursion Pharmaceuticals in the third quarter worth approximately $61,000. Finally, Daiwa Securities Group Inc. increased its position in shares of Recursion Pharmaceuticals by 29.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock worth $64,000 after acquiring an additional 2,883 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.